Kimiaki Takagi

13PUBLICATIONS
9CO-AUTHORS
Predictive and prognostic markersAutonomic nervous systemCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsEpidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Sep 15, 2026
Correction: Iinuma et al. Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab. J. Clin. Med. 2021, 10, 5325.

|Sep 12, 2026
Preoperative Diagnosis of Bladder Paraganglioma Followed by Robot-Assisted Partial Cystectomy: A Case Report.

|Jun 26, 2024
Impact of Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study.

Naotaka Kumada, Koji Iinuma, Yasuaki Kubota

|Feb 11, 2023
The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study.

Koji Iinuma, Toyohiro Yamada, Koji Kameyama

|Nov 10, 2022
CALN1 hypomethylation as a biomarker for high-risk bladder cancer.

Kimiaki Takagi, Azumi Naruse, Kazutoshi Akita

|Oct 14, 2022
Effectiveness and Safety of Molecular-Targeted Therapy after Nivolumab Plus Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study.

Koji Iinuma, Koji Kameyama, Tomoki Taniguchi

Pageof 3

Frequent Collaborators

10 joint publications

Takuya Koie

9 joint publications

Daiki Kato

6 joint publications

Koji Iinuma

5 joint publications

Tomoki Taniguchi